The following parameters were compared before and 6 and 12 months after using dupilumab: clinical parameters (frequency of asthma exacerbations and hospitalizations, the use of OCs, anosmia, SNOTT-22, and the ACT), FEV1, and laboratory parameters (serum IgE and eosinophilic count). The gene discussed is IGHE; the disease is asthma.